2025 NFXF WEBINAR SERIES
Industry Updates
There is a lot of work being done in the Fragile X research space! The NFXF is committed to keeping you up-to-date so you can consider available research opportunities for your family. Through this webinar, we get to connect you directly with our Industry Partners for annual updates on their Fragile X research.
This year, representatives from Shionogi, Mirum Pharma, Kaerus Bioscience, and Servier Pharmaceuticals will join us to share updates about their Fragile X programs. The webinar will be a series of short presentations from each Industry Partner on their Fragile X program, with a Q&A after all presentations, moderated by Anna De Sonia.
Our Industry Partners have been hard at work, and we’re looking forward to having them share their updates! We recommend reviewing the compilation of resources at the links below and coming prepared with your questions. You may also submit your questions in advance when completing your registration.
- A Video Message from Shionogi
- Mirum Pharmaceuticals to Launch Phase 2 Trial of MRM-3379 for Fragile X Syndrome
- Kaerus Bioscience Demonstrates Promise for KER-0193 BK Channel Modulator for Fragile X Syndrome
- Servier Pharmaceuticals Acquires Potential Treatment for Fragile X syndrome
We will do our best to answer everyone's questions. If you have additional questions, feel free to email us at contact@fragilex.org.
The webinar will be recorded and available to all registrants.